<DOC>
	<DOCNO>NCT01572688</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness melphalan injection autologous stem cell transplant multiple myeloma</brief_summary>
	<brief_title>Safety Efficacy Study High Dose Melphalan Treat Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients great equal 18 year , upper age limit 65 year eligible . Multiple myeloma patient , symptom conform diagnosis multiple myeloma IMWG2003/WHO2008 criterion . Patients responsive disease induction therapy 6 course treatment A complete response A good partial response A partial response At least 4 week long last cytotoxic treatment ( exclude Bortezomib , thalidomide , dexamethasone ) ; Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Patient absolute neutrophil count ≥1.5×109/L platelet count≥80×109/L ; Calculated creatinine clearance ＞50ml/min CockcroftGault formula collect urine within 24 hour . Patient total bilirubin ≤1.5 time normal upper limit , AST , ALT≤2.5times normal upper limit ; Cardiopulmonary function adequate conduct autologous stem cell transplant . Ratio body weight ideal body weight ＜175 % ; All patient life expectancy 12 week Signed informed consent form voluntarily CD34 positive hematopoietic stem cell collect ＜2.0×106/kg Patients psychiatric history Female subject pregnant breastfeeding Patients hypersensitive trial product alkylating agent Participate clinical trial within past 4 week Active CNS lesion Concomitant active infection positive HIV antibody Concomitant unhealed malignancy Left ventricular ejection fraction≤50 % Patients serious thrombosis Any severe concomitant disease expose study subject unacceptable risk . Patients suitable enroll investigator consideration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>